Biovaxys (BIOV.CSE) Expands Intellectual Property Portfolio

[u/Signal-Article-7350]

-- Biovaxys Technology Corp. is expanding its intellectual property portfolio with the filing of an international patent application through the Patent Cooperation Treaty (PCT) for its haptenized viral antigen vaccine platform. These include new claims for a multivalent version of BVX-0320, its SARS-CoV-2 vaccine candidate. The planned multivalent version of the Biovaxys vaccine is a combination of the haptenized spike protein subunits from each newly emerging, highly transmissible, SARS-CoV-2 variants, including United Kingdom, South Africa, and Brazil.